|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum tumor marker CA125 for monitoring ovarian cancer dur- ing follow-up显示文摘 | Tuxen MK Soletormos G Dombernowsky P | 2002 | Scand J Clin Lab Invest2002，62，24： | 1 |
| 2 | Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase Ⅱ study in patients with refractory and sensitive disease 显示文摘 | Ardizzoni A Hansen H Dombernowsky P | 1997 | J Clin Oncol1997，15，5： | 1 |
| 3 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate显示文摘 | Smith I Falkson G | 1998 | J Clin Oncol1998，16，： | 1 |
| 4 | Treatment of drug-induced nausea and vomiting显示文摘 | Herrsted J Dombernowsky P | 1994 | Ugeskr Jaeger1994，156，4： | 1 |
| 5 | Letrozole, a new oral arom atase inhibitor for advanced breast cancer: double-blind randomized trial showi ng a dose effect and improved efficacy and tolerability compared with megestrol acetate显示文摘 | Dombernowsky P Smith I Falkson G | 1998 | J Clin Oncol1998，16，2： | 1 |
| 6 | Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung Cancer显示文摘 | Stenbygaard LE Dombernowsky P | 1999 | Ann Oncol1999，10，9： | 1 |
| 7 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate 显示文摘 | Dombernowsky P Smith I Falkson G | 1998 | J Clin Oncol1998，16，2： | 1 |
| 8 | Serum tumormarker CA 125 for monitoring ovarian cancer during follow-up显示文摘 | Tuxen MK Soletormos G Dombernowsky P | 2002 | Scand J Clin Lab Invest2002，62，： | 1 |
| 9 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double -blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate 显示文摘 | Dombernowsky P Smith L Falkson G | 1998 | J Clin Oncol1998，16，2： | 1 |
| 10 | Topotecan,a new active drug in the second-line treatment of small-cell lung cancer:a phase Ⅱ study in patients with refractory and sensitive disease显示文摘 | Ardizzoni A Hansen H Dombernowsky P | 1997 | J Clin Oncol1997，15，5： | 1 |
| 11 | Letrozole,a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate 显示文摘 | Dombernowsky P Smith I Falkson G | 1998 | J Clin Oncol1998，16，： | 1 |
| 12 | Anti-emetic therapy in cancer chemotherapy:current status显示文摘 | Herrstedt J Dombernowsky P | 2007 | Basic Clin Pharmacol Toxicol2007，101，3： | 1 |
| 13 | Topotecan,a new active drug in the second line treatment of small cell lung cancer:a phase Ⅱ study in patients with refractory and sensitive disease 显示文摘 | Hansen H Dombernowsky P | 1997 | J Clin Oncol1997，15，5： | 1 |
| 14 | Teniposide(VM-26),an overlooked highly active agent in small cell lung cancer-Results of a phase Ⅱ trial in untreated patients显示文摘 | Hansen M Dombernowsky P | 1986 | J Clin Oncol1986，4，： | 1 |
| 15 | Brain metastases in adenocarcinoma of the lnng:frequency,risk groups and prognosis显示文摘 | Sorensen JB Hansen HH Hansen M Dombernowsky P | 1988 | J Clin Oneol1988，6，： | 1 |
| 16 | A new or- al aromatase inhibitor for advanced breast cancer: double- blind randomized trial showing a dose effect and improved efficacy and tolerability compared with mege- strol acetate显示文摘 | Dombernowsky P Smith I Falkson G | 1998 | J Clin Oncol1998，16，2： | 1 |
| 17 | Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis 显示文摘 | Sφrensen JB Hansen HH Hansen M Dombernowsky P | 1988 | J Clin Oncol1988，6，： | 1 |
| 18 | Letrozole,a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate显示文摘 | Dombernowsky P Smith I Falkson G et al | 1998 | J Clin Oncol1998，16，2： | 1 |
| 19 | Tumor markers in the management of patients with ovarian cancer显示文摘 | TUXEN MK SOLITORMOS G DOMBERNOWSKY P | 1995 | Cancer Treat Rev1995，21，3： | 1 |
| 20 | Serum tumour marker CA125 in monitoring of ovarian cancer during first-line chemotherapy显示文摘 | Tuxen MK Soletormos G Dombernowsky P | 2001 | Br J Canc-er2001，84，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员